NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Silo Pharma, Inc. SILO
11 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$72,102
▲ 0.0% vs FY2024
EPS · FY25
$-0.50
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-74.6%
Net margin · FY25
-5863.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 72,102.00
Revenue, FY2025 · full 11-year series below
Revenue
Net income
The company lost 5863 cents on every revenue dollar this year.
Per share
USD -0.50
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-74.6%
Return on equity, FY2025
ROE
Operating margin-5937.0%
Net margin-5863.5%
Return on assets-56.3%
Each USD of equity lost 75 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+12.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+0.0%
+12.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years+63.5%
Change, 10 years—
The share count grew 64% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 7.6M
total assets, end of FY2025
Total assetsUSD 7.6M
EquityUSD 6.3M
CashUSD 4.7M
Current ratio11.36×
Equity funds 83% of total assets.
History
11 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2012
2011
Revenue $B
0.0
0.0
0.0
0.0
·
0.0
0.0
·
·
·
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
EBITDA $B
·
·
·
·
·
·
·
·
·
·
·
Income tax $B
·
·
·
·
0.0
·
·
·
·
·
·
Net income $B
−0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
−0.0
0.0
−0.0
−0.0
EPS, diluted $
−0.50
−1.19
−1.20
·
0.04
−0.05
−0.04
−0.02
0.01
0.00
0.00
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
ROE %
−74.6
−78.4
−44.8
−40.3
75.5
−483.0
−527.0
−120.4
29.6
·
·
Shares out B
0.01
0.00
0.00
0.00
0.00
0.09
0.02
0.02
0.05
0.03
0.03
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
37 of 37
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed